A. Wunder

490 total citations
23 papers, 380 citations indexed

About

A. Wunder is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, A. Wunder has authored 23 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in A. Wunder's work include Radiopharmaceutical Chemistry and Applications (4 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Cancer Treatment and Pharmacology (3 papers). A. Wunder is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (4 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Cancer Treatment and Pharmacology (3 papers). A. Wunder collaborates with scholars based in Germany, United States and Switzerland. A. Wunder's co-authors include H. Sinn, Jan Klohs, Ulrich Dirnagl, G. Stehle, W. Maier‐Borst, D. L. Heene, H. H. Schrenk, E. Friedrich, Steffen Gay and Ulf Müller‐Ladner and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Proceedings of the IEEE.

In The Last Decade

A. Wunder

22 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Wunder Germany 9 120 115 96 79 56 23 380
Dennis S. W. Lee Canada 8 139 1.2× 76 0.7× 50 0.5× 37 0.5× 115 2.1× 12 663
Asim M. Akhtar United Kingdom 6 101 0.8× 70 0.6× 64 0.7× 95 1.2× 22 0.4× 9 335
Hye-Yeong Kim United States 11 94 0.8× 48 0.4× 90 0.9× 48 0.6× 65 1.2× 16 361
Péter Várallyay Hungary 7 73 0.6× 84 0.7× 134 1.4× 161 2.0× 26 0.5× 13 407
Rüdiger Bantleon Germany 9 97 0.8× 75 0.7× 145 1.5× 139 1.8× 43 0.8× 17 413
Ryuta Sato Japan 11 149 1.2× 81 0.7× 55 0.6× 107 1.4× 82 1.5× 25 385
Elise Lavergne France 14 248 2.1× 30 0.3× 71 0.7× 58 0.7× 262 4.7× 16 665
Lenneke Prinzen Netherlands 11 126 1.1× 44 0.4× 88 0.9× 50 0.6× 29 0.5× 14 533
Timothy S. Mulligan United States 10 254 2.1× 76 0.7× 22 0.2× 19 0.2× 104 1.9× 14 497
Gesa Ladewig Germany 7 87 0.7× 155 1.3× 183 1.9× 24 0.3× 21 0.4× 8 367

Countries citing papers authored by A. Wunder

Since Specialization
Citations

This map shows the geographic impact of A. Wunder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Wunder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Wunder more than expected).

Fields of papers citing papers by A. Wunder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Wunder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Wunder. The network helps show where A. Wunder may publish in the future.

Co-authorship network of co-authors of A. Wunder

This figure shows the co-authorship network connecting the top 25 collaborators of A. Wunder. A scholar is included among the top collaborators of A. Wunder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Wunder. A. Wunder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mehnert, Jan, et al.. (2012). Noninvasive Fluorescence Imaging in Animal Models of Stroke. Current Medicinal Chemistry. 19(28). 4786–4793. 5 indexed citations
3.
Wunder, A., et al.. (2010). Analysis of resilience scores of breast cancer patients undergoing ambulatory chemotherapy treatment.. Journal of Clinical Oncology. 28(15_suppl). e19681–e19681. 1 indexed citations
4.
Wunder, A., et al.. (2009). Analysis of resilience scores in a cohort of solid tumors ambulatory cancer patients in chemotherapy treatment. Journal of Clinical Oncology. 27(15_suppl). e20736–e20736. 1 indexed citations
5.
Steinbrink, Jens, Adam Liebert, Heidrun Wabnitz, et al.. (2008). Towards Noninvasive Molecular Fluorescence Imaging of the Human Brain. Neurodegenerative Diseases. 5(5). 296–303. 36 indexed citations
6.
Wunder, A., Jan Klohs, & Ulrich Dirnagl. (2008). Non-invasive visualization of CNS inflammation with nuclear and optical imaging. Neuroscience. 158(3). 1161–1173. 50 indexed citations
7.
8.
Wunder, A., et al.. (2005). Molecular imaging: novel tools in visualizing rheumatoid arthritis. Lara D. Veeken. 44(11). 1341–1349. 38 indexed citations
9.
Grimm, Jan & A. Wunder. (2005). Molekulare Bildgebung: Stand der Forschung. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 177(3). 326–337. 7 indexed citations
10.
Wunder, A., et al.. (2005). From Genomics to Clinical Molecular Imaging. Proceedings of the IEEE. 93(4). 819–828. 16 indexed citations
11.
Wunder, A., et al.. (2003). Molekulare Bildgebung bei rheumatoider Arthritis. Zeitschrift für Rheumatologie. 62(0). 1–1. 3 indexed citations
12.
Wunder, A., Ulf Müller‐Ladner, Ernst H. K. Stelzer, et al.. (2003). Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. Arthritis Research. 5(Suppl 3). 9–9. 8 indexed citations
13.
Hartung, G., S. Heeger, Thomas Bertsch, et al.. (2000). Adaptation and Clinical Evaluation of a Homogenous Enzyme Multiplied Immunoassay Technique (EMIT) for Drug Monitoring of a Methotrexate-Albumin Conjugate (MTX-HSA) in Humans. Oncology Research and Treatment. 23(4). 352–357. 3 indexed citations
14.
Kremer, Paul, A. Wunder, H. Sinn, et al.. (2000). Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: Experimental and preliminary clinical results. Neurological Research. 22(5). 481–489. 35 indexed citations
15.
Hartung, G., G. Stehle, H. Sinn, et al.. (1999). Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.. PubMed. 5(4). 753–9. 81 indexed citations
16.
Hartung, G., G. Stehle, S. Heeger, et al.. (1999). Drug monitoring and pharmacokinetics of a methotrexate-albumin conjugate (MTX-HSA) in cancer patients with long term remission. European Journal of Cancer. 35. S295–S295. 1 indexed citations
17.
Wunder, A., G. Stehle, H. Sinn, et al.. (1997). Enhanced albumin uptake by rat tumors. International Journal of Oncology. 11(3). 497–507. 59 indexed citations
18.
Wunder, A., G. Stehle, H. Sinn, et al.. (1997). Antitumor activity of MTX-SA conjugates in rats. European Journal of Cancer. 33. S178–S179. 2 indexed citations
19.
Wunder, A., G. Stehle, H. Sinn, et al.. (1995). The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat. Thrombosis Research. 78(2). 139–149. 5 indexed citations
20.
Stehle, G., E. Friedrich, H. Sinn, et al.. (1992). Hepatic uptake of a modified low molecular weight heparin in rats.. Journal of Clinical Investigation. 90(5). 2110–2116. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dennis S. W. Lee Breakdown of academic impact, for papers by Asim M. Akhtar Breakdown of academic impact, for papers by Hye-Yeong Kim Breakdown of academic impact, for papers by Péter Várallyay Breakdown of academic impact, for papers by Rüdiger Bantleon Breakdown of academic impact, for papers by Ryuta Sato Breakdown of academic impact, for papers by Elise Lavergne Breakdown of academic impact, for papers by Lenneke Prinzen Breakdown of academic impact, for papers by Timothy S. Mulligan Breakdown of academic impact, for papers by Gesa Ladewig
Rankless by CCL
2026